WuXi PharmaTech has split in two its clinical-stage China CRO JV with PRA Health Sciences of North Carolina. WuXi will take over control of the CRO's China operations, bringing them entirely in-house, and PRA will own the Hong Kong business. The two companies joined forces in 2013. PRA, a global CRO, added its China-based staff and global technology capabilities, including data capture, trial management and other IT systems. The current "restructuring," as it is being called, came at the request of WuXi.
